Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients
- 1 April 2000
- journal article
- clinical trial
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 28 (4) , 423-433
- https://doi.org/10.1016/s0090-9556(24)15060-x
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.Published by Elsevier ,2021
- Photodegradation of Irinotecan (CPT-11) in Aqueous Solutions: Identification of Fluorescent Products and Influence of Solution CompositionJournal of Pharmaceutical Sciences, 1997
- The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes Differential hydrolysis for the lactone and carboxylate formsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1997
- CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinantsInternational Journal of Cancer, 1997
- Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecanCancer Chemotherapy and Pharmacology, 1995
- Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urineCancer Chemotherapy and Pharmacology, 1995
- The structural basis of camptothecin interactions with human serum albumin: impact on drug stabilityJournal of Medicinal Chemistry, 1994
- Canalicular organic anion transport after bile duct ligation and reconstructicn in the ratHepatology, 1993
- Plasma Pharmacokinetics of the Lactone and Carboxylate Forms of 20(S)-Camptothecin in Anesthetized RatsPharmaceutical Research, 1993
- High-performance liquid chromatographic analysis, plasma protein binding and red blood cell partitioning of phenprobamateBiopharmaceutics & Drug Disposition, 1987